UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

 

Hematology Highlights: A Post ASH Review
15:04

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

New Therapies in AML: Is It Safe to Wait for Genomic Info to Start Therapy? How To Tailor the Therapy? Data on Targeting BCL-2 with Venetoclax

FEATURING Eunice Wang
  • 367 views
  • March 9, 2020
  • 3
13:32

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

AML Treatment Options: Modulating p53 Pathways, Targeting FLT3 Inhibitors and IDH Mutations & Maintenance Therapy

FEATURING Eunice Wang
  • 324 views
  • March 9, 2020
  • 1
10:46

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Harnessing the Immune System - Immunotherapy for AML, Targeting Antigens and Novel Antibodies, T-cell Directed Therapy

FEATURING Eunice Wang
  • 24 views
  • March 9, 2020
18:28

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Malignancy-Associated Thrombosis: DOACs in Treatment of Cancer-Associated Thrombosis, Use of DOACs for Prophylaxis & Bleeding Risk for Pts With PV

FEATURING Brandon J. McMahon
  • 780 views
  • March 9, 2020
  • 2
14:19

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombosis in Antiphospholipid Ab Syndrome & Andexanet and Idarucizumab Safe and Effective at Reversing Anticoagulant Effects of DOACs

FEATURING Brandon J. McMahon
  • 213 views
  • March 9, 2020
  • 1
10:47

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide Combinations

FEATURING Nathan H. Fowler
  • 241 views
  • March 9, 2020
  • 2
11:25

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss and Overcoming Resistance, Targeting CD19 and CD22 & BiTEs

FEATURING Nathan H. Fowler
  • 1,075 views
  • March 9, 2020
  • 2
08:20

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CAR T-cell for MCL, LOXO-305 Effective in Pretreated B-Cell, Nivo and Brentuximab Looks Effective, Nivo Showed Limited Activity in R/R PTCL

FEATURING Nathan H. Fowler
  • 258 views
  • March 9, 2020
11:56

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VMP for Transplant-ineligible Pts, D-RVd as a Potential SOC for Transplant-eligible Pts & Prognostic Value of PET-CT

FEATURING Ashley Rosko
  • 21 views
  • March 9, 2020
09:20

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy for NDMM & Cost and Quality of Anti-Resorptive Agents

FEATURING Ashley Rosko
  • 225 views
  • March 9, 2020
  • 2
15:31

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to Venetoclax, Venetoclax Combinations, CAR T Trials & Anti-BCMA CAR T-cell Therapy

FEATURING Ashley Rosko
  • 133 views
  • March 9, 2020
  • 1
17:27

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and OS, Fixed Duration Venetoclax/Obinutuzumab, Acalabrutinib Safe and Effective

FEATURING R. Gregory Bociek
  • 322 views
  • March 9, 2020
15:39

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CLL Highlights from ASH: Chemo Free Therapy Achieves MRD Clearance, AVO Effective as Frontline Therapy, Time-limited Therapy with Ven+Ritux for R/R Disease

FEATURING R. Gregory Bociek
  • 49 views
  • March 9, 2020
09:52

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Impact of Next Generation Sequencing on MDS, Scoring System & Clonal Hematopoiesis and Risk of Developing MDS

FEATURING Hetty E. Carraway
  • 19 views
  • March 9, 2020
17:41

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenalidomide, Luspatercept, Roxadustat and TP53 Mutations

FEATURING Hetty E. Carraway
  • 186 views
  • March 9, 2020
  • 1
13:11

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Emerging Therapies in MDS: Novel Oral HMT May Become Basis of New Backbone Therapy for MDS and AML & Combination Therapies with HMT Appear Promising

FEATURING Hetty E. Carraway
  • 218 views
  • March 9, 2020
  • 1
13:21

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 AML Update: Is It Safe to Wait for Genomic Info to Start Therapy? & Maintenance Therapy With Azacitidine and Decitabine

FEATURING Eunice Wang
  • 149 views
  • March 9, 2020
  • 1
12:03

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 AML Update: Ven-based Therapy Can Provide a Path to AlloSCT, Combination Regimens are the Future of AML Therapy

FEATURING Eunice Wang
  • 77 views
  • March 9, 2020
08:48

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Results, Dasatinib + Blina Induction for Older Ph+, Best TKI to Use in Frontline Setting

FEATURING Eunice Wang
  • 27 views
  • March 9, 2020
13:02

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Current Treatment Algorithm & Disease Complications in ET, PV, Myelofibrosis

FEATURING Ayalew Tefferi
  • 1,350 views
  • March 9, 2020
  • 7
17:47

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Update in MPN: Triple Negative ET, Ropeginterferon in PV & Fedratinib, Luspatercept and Emerging Epigenetic-based Therapies in Myelofibrosis

FEATURING Ayalew Tefferi
  • 32 views
  • March 9, 2020